Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade
Pulmonary arterial hypertension (PAH) is a rare but well-known cardiovascular condition potentially associated with human immunodeficiency virus (HIV) infection and is currently recognized to be one of the most ominous noninfectious HIV complications. Although there is no clear evidence supporting t...
Main Authors: | Valerio Zacà, Marco Metra, Rossella Danesi, Carlo Lombardi, Giulia Verzura, Livio Dei Cas |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2009-02-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753465808101549 |
Similar Items
-
Anemia and heart failure: a cause of progression or only a consequence?
by: Livio Dei Cas, et al.
Published: (2007-06-01) -
Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
by: Eve-Irene Lepist, et al.
Published: (2014-01-01) -
Use of a nonselective endothelin receptor antagonist in idiopathic pulmonary hypertension
by: Ol'ga Aleksandrovna Arkhipova, et al.
Published: (2010-11-01) -
NEBIVOLOL: HAEMODYNAMIC EFFECTS AND CLINICAL SIGNIFICANCE OF COMBINED BETA-BLOCKADE AND NITRIC OXIDE RELEASE
by: Otto Kamp, et al.
Published: (2010-08-01) -
A review of sitaxsentan sodium in patients with pulmonary arterial hypertension
by: Aaron B Waxman
Published: (2007-03-01)